The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

Objective: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepa...

Full description

Bibliographic Details
Main Authors: Kristine Griffett, Ryan D. Welch, Colin A. Flaveny, Grant R. Kolar, Brent A. Neuschwander-Tetri, Thomas P. Burris
Format: Article
Language:English
Published: Elsevier 2015-04-01
Series:Molecular Metabolism
Subjects:
NASH
Fibrosis
Lipogenesis
LXR
Inflammation
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877815000228

Internet

http://www.sciencedirect.com/science/article/pii/S2212877815000228

Similar Items